The advent of next-generation sequencing (NGS) has meant better care for children with acute myeloid leukemia (AML), a better understanding of rare subtypes of genetic AML, and a better prognosis for these patients, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
The advent of next-generation sequencing has meant better care for children with acute myeloid leukemia (AML), a better understanding of rare subtypes of genetic AML, and a better prognosis for these patients, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Transcript
How is genetic testing being used in pediatric tumors?
Genetic testing is critical. I think the evolution of affordable and rapid turnaround time with next-generation sequencing has revolutionized our care of children with AML. We now know so much more about very rare subtypes of genetic AML and children. We have done a lot of work retrospectively through the Children's Oncology Group, as well as our collaborators and some of the European pediatric oncology consortia to really understand, you know, what the relapse risk with the overall survival is of some children who have extremely, sometimes cytogenetically cryptic molecular features.
So, we now know there are probably 40 different types of childhood AML with respect to genetic stratification, and now that we are a little bit able better able to understand what the prognosis is of some of these, I think it's really helping us to understand who our highest risk patients are. We will, in our upcoming trials, start transplanting more patients in first remission based on genetics that we didn't previously know about. And I think it's also going to help us to identify patients in particular who may be best suited for immunotherapies later, that we know from the get-go, the time that they're diagnosed, that they are at very high risk of relapse. And we don't always know that transplant improves overall survival for some of these children.
And so, I think genetic testing will really help us to implement any of the therapy application better.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More